# Public summary document

**Product:** Dansac NovaLife 1 Open Flat GX+ Clear (Maxi)

**Applicant:** Liberty Medical PTY LTD (Dansac)

**Date of SPAP Meeting:** 26 April 2022

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Liberty Medical PTY LTD (Dansac), sought the deletion of one variant in existing product range of Dansac NovaLife 1 Open Flat GX+ Clear (Maxi) (SAS Code 80069E) in subgroup 2(a) of the Stoma Appliance Scheme (SAS) Schedule, as the product has been discontinued. The product, including five variants, is currently listed at a unit price of $4.879 with a maximum monthly quantity of 30 units. The applicant has not sought deletion of the remaining four variants.

## Substitute products

Dansac NovaLife 1 Piece Open Flat (SAS 3954D).

## Variants to be deleted

| **Product Code** | **Description** |
| --- | --- |
| 962-10 | protected single carbon filter, transparent with fabric backing, large, 550ml, low headspace, integrated closure, no belt loops, 1.1mm, hydrocolloid baseplate, hydrocolloid self-adhesive, standard wear, oval, cut-to-fit, 10mm, release tabs, 55mm |

## Background

This product was first listed on the SAS Schedule on 1 April 2016.

## Clinical Place for the Product

Not applicable.

## Financial Analysis

Substitute products are currently listed in subgroup 2(a) of the SAS Schedule at the same cost and maximum monthly quantity. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

## Panel Recommendation

The Panel, noting an equivalent product remained on the Schedule recommended the deletion of one variant from the product range for Dansac NovaLife 1 Open Flat GX+ with EasiView and Clear (Maxi) (SAS Code 80069E) listed in subgroup 2(a) of the SAS Schedule at the unit price of $4.879 with a maximum monthly quantity of 30 units.

The Panel also noted that ConvaTec Australia PTY LTD is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the Panel recommended date (26 April 2022) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Recommendation

The Panel provides advice on whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. Applications are considered in this context. Panel advice not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following advice not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

The applicant noted the SPAP recommendation.